OpusPoint Partners: Investing in Biotechnology’s Future
Advancements in the areas of life science and biotechnology are what OpusPoint Partners are all about. The company encourages original development of biotechnology ideas and supports those businesses that encompass a pioneering spirit. OpusPoint Partners consistently utilizes its knowledge of both the financial and healthcare world to make a difference in human health.
OpusPoint Partners first came together in 2009; the company is the product of Michael Weiss and Lindsay Rosenwald, M.D. This is the first combined venture for Rosenwald and Weiss, though individually they have been garnered much success in the life science and biotech industries. Both men bring over 20 years experience to the company; this includes founding and financing numerous biotechnology companies of their own over the years.
For Lindsay Rosenwald, one of his most recent individually successful ventures outside of OpusPoint Partners was his formation of Cougar Biotechnology Inc. This biotech company is located in Southern California and primarily researches and develops drugs to help combat cancer. Cougar Biotech has had some success with a drug for prostate cancer and has obtained the interest of researchers and investors alike. In 2009 Johnson & Johnson took notice and purchased the company for roughly one billion dollars.
OpusPoint Partners holds steadfast to expecting its associated biotech companies to abide by Rosenwald’s and Weiss’ strong principles of ethics in research and drug trials. OpusPoint Partners specifically looks for those biotech companies who have innovative ideas and the beginning foundation of sound business standards. Maintaining a business standard that crosses the board ensures the investors that their financial support is indeed secure. This investor confidence in turn aids in the development of the emergent biotech firms operating under the guidance of OpusPoint Partners and subsequently leads to necessary breakthroughs in the healthcare industry.
Lindsay Rosenwald is considered as a mentor of sorts to those biotechnology firms that OpusPoint Partners invests in; he brings his extensive expertise into play when he assists these companies in reaching their business goals. Because he has spent over 20 years in the same industry both creating and managing in excess of 50 biotech firms during this time, Rosenwald has much to offer these budding companies in an advisory context. Even though gaining appropriate financial backing is a key aspect for any emerging company, finding a mentor who can guide you to your end goal unimpeded is just as essential.
With Lindsay Rosenwald taking the lead at OpusPoint Partners, both individual and corporate investors can breathe a sigh of relief knowing that their investments are being managed properly and that transparency in the company’s dealings are being maintained. Rosenwald’s academic knowledge and professional experience in both the healthcare and financial sectors has proven to be an asset for OpusPoint Partners and its investors. He has shown that he understands what is required for a biotech firm to succeed and lay new groundwork in the medical field and because of this know-how the company has certainly shown their investors that minimal risk and optimal growth is attainable with OpusPoint Partners.
Lindsay Rosenwald brings a lot to the OpusPoint Partners table; he has spent a total of 17 years working in both finance on Wall Street and in developing biotechnology companies. Rosenwald’s academic pursuits include receiving a Bachelor of Science in Finance from Pennsylvania State University and a Doctor of Medicine from Temple University School of Medicine.
Rosenwald’s background in finance has proven quite useful in his career. From 1994 – 2007 he managed the Aries Fund, during 2000 alone he oversaw in excess of one billion in investments toward healthcare in this fund. He also managed the investments of the Orion Fund (2002 to 2006) whose funds are dedicated exclusively to biotechnology.
OpusPoint Partners along with Lindsay Rosenwald have their goals set on finding the brightest and most progressive biotechnology companies to invest in. It is these truly unique companies that will diligently and ethically work to create new technologies and drugs that will change the face of the healthcare industry as we know it.
OpusPoint Partners is a company that stands out for all of the right reasons. The co-founders Rosenwald and Weiss have over a short two year time span built up a well respected company that abides attentively to their inner moral compass. They do no encourage cutting corners or tampering with research or clinic trials, they do however promote the idea of upholding integrity in all aspects of the business world.
Making a change in the healthcare industry is no easy task, Lindsay Rosenwald along with OpusPoint Partners activity recognize this challenge. But, he doesn’t let this hinder him from staying the course and continuing to push down barriers in the life science and biotechnology fields. OpusPoint Partners and its associates continue to keep their aspirations on the ultimate prize, eradication of disease.
Because of the companies tenacity in biotechnology it is obvious to those operating in the both the financial and healthcare sectors that OpusPoint Partners is an investing do and not an investing don’t. Lindsay Rosenwald prides the OpusPoint Partners success on the fact that investors are privy to the financial dealings of the company every step of the way and the emergent biotech firms that are backed by investors are selected for their ingenuity, growth potential, and ethical principles.
Lindsay Rosenwald is constantly pursuing new investment leads in order to continue the expansion of OpusPoint Partners and to get closer to making significant advances in healthcare. When he is not focusing on his professional pursuits, Rosenwald takes part on the Board of Directors of the Republican Jewish Coalition.